ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Government Awards Flu Vaccine Contracts

by Rick Mullin
March 7, 2011 | APPEARED IN VOLUME 89, ISSUE 10

Novavax has been awarded a contract valued at up to $179 million by the Biomedical Advanced Research & Development Authority (BARDA) for development of recombinant vaccines for the prevention of seasonal and pandemic influenza. During the contract’s three-year base period, valued at $97 million, the company will develop and manufacture its clinical-stage virus-like-particle vaccines. The contract could be extended an additional two years with $82 million in funding. BARDA, part of the Department of Health & Human Services, has awarded a similar flu vaccine contract to VaxInnate. It is valued at up to $196 million, including a $118 million three-year base period and an option to extend for two years.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment